BC
ALNY icon

Bayforest Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bayforest Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-71
Closed -$23.5K – 941
2026
Q1 		$23.5K Sell
71
-341
-83% -$116K 0.03% 707
2025
Q4 		$164K Buy
+412
New +$182K 0.12% 340
2025
Q2 		– Sell
-306
Closed -$82.6K – 720
2025
Q1 		$82.6K Buy
306
+39
+15% +$10K 0.04% 507
2024
Q4 		$62.8K Buy
+267
New +$70.2K 0.08% 425

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bayforest Capital's ALNY Position: Q2 2026 in Review

Bayforest Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 71 shares — an estimated $23.5K sold.

Bayforest Capital first reported a position in ALNY in Q4 2024 and held it in 4 quarters. The position peaked at $164K in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Bayforest Capital reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bayforest Capital sold 71 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $23.5K.
  • Bayforest Capital first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • Bayforest Capital's Alnylam Pharmaceuticals position peaked at $164K in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Bayforest Capital's 13F filing for Q2 2026, filed 5 Aug 2026.